Eversept Partners, LP Viking Therapeutics, Inc. Transaction History

Eversept Partners, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$47.39 - $80.2 $5.48 Million - $9.28 Million	115,671 Added 506.93%	138,489 $7.34 Million
Q1 2024 May 15, 2024	BUY	$17.4 - $94.5 $397,033 - $2.16 Million	22,818 New	22,818 $1.87 Million
Q4 2018 Feb 13, 2019	SELL	$7.16 - $16.21 $179,000 - $405,250	-25,000 Closed	0 $0
Q3 2018 Nov 08, 2023	BUY	$9.7 - $19.65 $242,499 - $491,249	25,000 New	25,000 $435,000
Q3 2018 Nov 14, 2018	BUY	$9.7 - $19.65 $242,499 - $491,249	25,000 New	25,000 $436,000

466

63.8M

5.76M

3.4M

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $2.6B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Eversept Partners, LP, based on Form 13F filings with the SEC.

Stay updated on Eversept Partners, LP with notifications on news.